These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23818353)

  • 1. A weekly hypofractionated radiotherapeutic schedule for bladder carcinoma in elderly patients: local response, acute and late toxicity, dosimetric parameters and pain relief.
    Zygogianni A; Kouloulias V; Armpilia C; Antypas C; Kantzou I; Balafouta M; Kyrgias G; Sarris G; Kelekis N; Kouvaris J
    J BUON; 2013; 18(2):407-12. PubMed ID: 23818353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of efficacy and toxicity in two different hypofractionated 3D-conformal external beam radiotherapy schedules in localised muscle invasive bladder cancer.
    Kouloulias V; Mosa E; Tolia M; Kantzou I; Koliarakis N; Platoni K; Georgakopoulos I; Siatelis A; Sarris G; Beli I; Chrisofos M; Kelekis N
    J BUON; 2013; 18(4):942-8. PubMed ID: 24344021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of acute toxicity and symptoms palliation in a hypofractionated weekly schedule of external radiotherapy for elderly patients with muscular invasive bladder cancer.
    Kouloulias V; Tolia M; Kolliarakis N; Siatelis A; Kelekis N
    Int Braz J Urol; 2013; 39(1):77-82. PubMed ID: 23489500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised trial of accelerated radiotherapy for localised invasive bladder cancer.
    Horwich A; Dearnaley D; Huddart R; Graham J; Bessell E; Mason M; Bliss J
    Radiother Oncol; 2005 Apr; 75(1):34-43. PubMed ID: 15878099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical hypofractionated accelerated radiotherapy with cytoprotection for invasive bladder cancer.
    Koukourakis MI; Tsolos C; Touloupidis S
    Urology; 2007 Feb; 69(2):245-50. PubMed ID: 17320657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant fractionated high-dose-rate intracavitary brachytherapy after external beam radiotherapy in Tl and T2 nasopharyngeal carcinoma.
    Lu JJ; Shakespeare TP; Tan LK; Goh BC; Cooper JS
    Head Neck; 2004 May; 26(5):389-95. PubMed ID: 15122654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A hypofractionated radiotherapy schedule with 57.75Gy in 21 fractions for T1-2N0 prostate carcinoma: Analysis of late toxicity and efficacy.
    Kouloulias V; Zygogianni A; Kantzou I; Tolia M; Platoni K; Antypas C; Chaldeopoulos D; Pantelakos P; Siatelis A; Chrysofos M; Beli I; Dilvoi M; Georgakopoulos I; Sarris G; Kouvaris J; Kelekis N
    J BUON; 2014; 19(3):763-9. PubMed ID: 25261664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.
    Al-mamgani A; Tans L; Van rooij PH; Noever I; Baatenburg de jong RJ; Levendag PC
    Acta Oncol; 2009; 48(4):562-70. PubMed ID: 19373698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypofractionated radiotherapy as definitive treatment of stage I non-small cell lung cancer in older patients.
    Ahmad E; Sandhu AP; Fuster MM; Messer K; Pu M; Nobiensky P; Bazhenova L; Seagren S
    Am J Clin Oncol; 2011 Jun; 34(3):254-8. PubMed ID: 20562588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM; Winter K; Purdy JA; Perez CA; Ryu JK; Parliament MB; Valicenti RK; Roach M; Sandler HM; Markoe AM; Cox JD
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):735-42. PubMed ID: 14967428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
    Cante D; Rosa La Porta M; Casanova-Borca V; Sciacero P; Girelli G; Pasquino M; Franco P; Ozzello F
    Breast J; 2011; 17(6):586-93. PubMed ID: 21951485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA; Thakkar VV; Khuntia D; Reddy CA; Klein EA; Mahadevan A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1463-8. PubMed ID: 16169683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients.
    Courdi A; Ortholan C; Hannoun-Lévi JM; Ferrero JM; Largillier R; Balu-Maestro C; Chapellier C; Ettore F; Birtwisle-Peyrottes I
    Radiother Oncol; 2006 May; 79(2):156-61. PubMed ID: 16698099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radical chemoradiotherapy for elderly patients with bladder carcinoma invading muscle.
    Arias F; Dueñas M; Martínez E; Domínguez MA; Illarramendi JJ; Villafranca E; Tejedor M; Molina F; Meiriño R; Valerdi JJ
    Cancer; 1997 Jul; 80(1):115-20. PubMed ID: 9210716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.